Amundi Acquires 444,376 Shares of Kenvue Inc. $KVUE

Key Points

• Amundi increased its stake in Kenvue Inc. by 5.9% in the first quarter, purchasing an additional 444,376 shares, bringing its total ownership to approximately 7,950,629 shares valued at $188 million.
• Kenvue's stock has seen a fluctuation with a 1-year low of $19.75 and a 1-year high of $25.17, and the company recently reported earnings per share of $0.29, exceeding expectations.
• The company announced a quarterly dividend increase to $0.2075, resulting in an annualized yield of 4.0%, despite a high payout ratio of 112.16%.

Amundi raised its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 5.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,950,629 shares of the company's stock after purchasing an additional 444,376 shares during the quarter. Amundi owned 0.41% of Kenvue worth $188,053,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Pittenger & Anderson Inc. acquired a new stake in Kenvue during the 1st quarter worth approximately $30,000. TruNorth Capital Management LLC bought a new position in shares of Kenvue during the first quarter valued at $36,000. Truvestments Capital LLC acquired a new position in shares of Kenvue during the first quarter worth $37,000. Clal Insurance Enterprises Holdings Ltd grew its stake in shares of Kenvue by 378.5% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock worth $39,000 after purchasing an additional 1,287 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich increased its holdings in Kenvue by 120.6% in the first quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company's stock valued at $41,000 after purchasing an additional 929 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Up 2.6%

NYSE:KVUE traded up $0.47 during trading hours on Tuesday, reaching $18.90. The company had a trading volume of 38,144,743 shares, compared to its average volume of 18,284,313. Kenvue Inc. has a twelve month low of $17.15 and a twelve month high of $25.17. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The firm has a market cap of $36.27 billion, a price-to-earnings ratio of 25.54, a P/E/G ratio of 2.67 and a beta of 0.83. The business's 50-day simple moving average is $21.32 and its two-hundred day simple moving average is $22.35.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company had revenue of $3.84 billion for the quarter, compared to analysts' expectations of $3.94 billion. During the same quarter in the prior year, the firm earned $0.32 EPS. The business's revenue was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, equities analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were given a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 4.4%. The ex-dividend date of this dividend was Wednesday, August 13th. This is an increase from Kenvue's previous quarterly dividend of $0.21. Kenvue's payout ratio is 112.16%.

Analysts Set New Price Targets

KVUE has been the topic of a number of analyst reports. Evercore ISI reduced their price target on Kenvue from $25.00 to $23.00 and set an "in-line" rating on the stock in a research report on Monday. Canaccord Genuity Group reduced their target price on Kenvue from $29.00 to $26.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Royal Bank Of Canada lowered their price target on shares of Kenvue from $24.00 to $22.00 and set a "sector perform" rating for the company in a report on Friday, August 8th. Citigroup reduced their price objective on shares of Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a research note on Tuesday, July 15th. Finally, Bank of America decreased their price objective on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a research report on Tuesday, July 15th. Five investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $24.21.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.